{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:02:04Z","timestamp":1791115324547,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,6,15]],"date-time":"2014-06-15T00:00:00Z","timestamp":1402790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,6,15]],"date-time":"2014-06-15T00:00:00Z","timestamp":1402790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10637-014-0125-2","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T07:57:46Z","timestamp":1403164666000},"page":"1213-1225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR\u2122 therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Ajay K.","family":"Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano R.","family":"Tarantolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Eisenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Stromatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,15]]},"reference":[{"issue":"15","key":"125_CR1","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(15):3383\u20133389. doi:10.1200\/JCO.2005.08.100","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"27","key":"125_CR2","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(27):4473\u20134479. doi:10.1200\/JCO.2008.17.0001","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"125_CR3","doi-asserted-by":"crossref","unstructured":"Fowler NH, Advani RH, Sharman JP, Smith SM, McGreivy J, Kunkel L, Troung V, Zhou C, Boyd TE (2013) The Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma American Society of Hematology Annual Meeting; December 7\u201310, 2013; New Orleans, LA","DOI":"10.1182\/blood.V120.21.156.156"},{"issue":"26","key":"125_CR4","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(26):6409\u20136414. doi:10.1200\/JCO.2005.55.017","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"32","key":"125_CR5","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(32):5404\u20135409. doi:10.1200\/JCO.2008.21.1169","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"125_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK 25(2):341\u2013347. doi:10.1038\/leu.2010.226","journal-title":"Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"issue":"4","key":"125_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12185-010-0707-5","volume":"92","author":"K Tobinai","year":"2010","unstructured":"Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K (2010) Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 92(4):563\u2013570. doi:10.1007\/s12185-010-0707-5","journal-title":"Int J Hematol"},{"issue":"4","key":"125_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.clml.2013.04.003","volume":"13","author":"B Coiffier","year":"2013","unstructured":"Coiffier B (2013) Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma. Clinical lymphoma, myeloma & leukemia 13(4):351\u2013359. doi:10.1016\/j.clml.2013.04.003","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"Suppl 2","key":"125_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","volume":"25","author":"K Bouabdallah","year":"2013","unstructured":"Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R (2013) Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol 25(Suppl 2):S1\u201312. doi:10.1097\/CCO.0b013e32835de8ee","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"125_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. The lancet oncology 12(4):361\u2013368. doi:10.1016\/S1470-2045(11)70062-6","journal-title":"The lancet oncology"},{"issue":"21","key":"125_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.V122.21.85.85","volume":"122","author":"AK Gopal","year":"2013","unstructured":"Gopal AK, Kahl BS, DeVos S, Wagner-Johnston ND, Schuster SJ, Blum KA, Wojciech JJ, Flinn IW, Flowers CR, Martin P, Viardot A, Goy A, Davies A, Zinzani PL, Dreyling M, Holes LM, Li D, Dancey R, Godfrey WR, Salles GA (2013) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell Non-Hodgkin lymphoma (iNHL). Blood 122(21):85","journal-title":"Blood"},{"issue":"2","key":"125_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24(2):203\u2013216. doi:10.1016\/j.beha.2011.02.009","journal-title":"Best Pract Res Clin Haematol"},{"key":"125_CR13","doi-asserted-by":"publisher","first-page":"15S","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"J Byrd","year":"2009","unstructured":"Byrd J, Lapalombella R, Ramanunni A, Andritsos L, Flynn J, Baum P, Thompson P, Muthusamy N (2009) Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:15S","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"125_CR14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","volume":"19","author":"S Barrena","year":"2005","unstructured":"Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A, Lazo PA (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK 19(8):1376\u20131383. doi:10.1038\/sj.leu.2403822","journal-title":"Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"issue":"11","key":"125_CR15","first-page":"4483","volume":"61","author":"L Belov","year":"2001","unstructured":"Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI (2001) Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 61(11):4483\u20134489","journal-title":"Cancer Res"},{"issue":"2","key":"125_CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ajcp\/96.2.184","volume":"96","author":"E Campo","year":"1991","unstructured":"Campo E, Cardesa A, Alos L, Palacin A, Cobarro J, Traserra J, Montserrat E (1991) Non-Hodgkin\u2019s lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study American journal of clinical pathology 96(2):184\u2013190","journal-title":"An immunohistochemical study American journal of clinical pathology"},{"issue":"4","key":"125_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/0046-8177(92)90092-H","volume":"23","author":"A Carbone","year":"1992","unstructured":"Carbone A, Pinto A, Gloghini A, Volpe R, Zagonel V (1992) B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to \u201cwell-differentiated\u201c lymphocytic disorders. Hum Pathol 23(4):438\u2013448","journal-title":"Hum Pathol"},{"issue":"7","key":"125_CR18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X Zhao","year":"2007","unstructured":"Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7):2569\u20132577. doi:10.1182\/blood-2006-12-062927","journal-title":"Blood"},{"issue":"3","key":"125_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","volume":"112","author":"AK Gopal","year":"2008","unstructured":"Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM (2008) Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112(3):830\u2013835. doi:10.1182\/blood-2008-01-132142","journal-title":"Blood"},{"issue":"10","key":"125_CR20","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","volume":"102","author":"I Jilani","year":"2003","unstructured":"Jilani I, O\u2019Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102(10):3514\u20133520. doi:10.1182\/blood-2003-01-0055","journal-title":"Blood"},{"issue":"3","key":"125_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2002-03-0876","volume":"101","author":"AD Kennedy","year":"2003","unstructured":"Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101(3):1071\u20131079. doi:10.1182\/blood-2002-03-0876","journal-title":"Blood"},{"issue":"15","key":"125_CR22","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1200\/jco.2009.27.15_suppl.8571","volume":"27","author":"PR Baum","year":"2009","unstructured":"Baum PR, Cerveny C, Gordon B (2009) Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin\u2019s lymphoma. J Clin Oncol 27(15):8571","journal-title":"J Clin Oncol"},{"key":"125_CR23","doi-asserted-by":"crossref","unstructured":"Algate PW, J.; Nilsson, C.; Sho, M.; Chao, D.; Starling, GC; Byrd, JC, Gordon, B. (2010) TRU-016, An Anti-CD37 SMIPTM Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin\u2019s Lymphoma. Blood 116:3931","DOI":"10.1182\/blood.V116.21.3931.3931"},{"issue":"9","key":"125_CR24","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2013-07-512137","volume":"123","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123(9):1302\u20131308. doi:10.1182\/blood-2013-07-512137","journal-title":"Blood"},{"issue":"5","key":"125_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(5):579\u2013586. doi:10.1200\/JCO.2006.09.2403","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"125_CR26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cct.2007.10.008","volume":"29","author":"S Ellis","year":"2008","unstructured":"Ellis S, Carroll KJ, Pemberton K (2008) Analysis of duration of response in oncology trials. Contemporary clinical trials 29(4):456\u2013465. doi:10.1016\/j.cct.2007.10.008","journal-title":"Contemporary clinical trials"},{"issue":"26","key":"125_CR27","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","volume":"115","author":"V Caruso","year":"2010","unstructured":"Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, Iacoviello L, Donati MB (2010) Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 115(26):5322\u20135328. doi:10.1182\/blood-2010-01-258624","journal-title":"Blood"},{"issue":"10","key":"125_CR28","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1002\/1097-0142(19910515)67:10<2579::AID-CNCR2820671030>3.0.CO;2-H","volume":"67","author":"M Al-Sharabati","year":"1991","unstructured":"Al-Sharabati M, Chittal S, Duga-Neulat I, Laurent G, Mazerolles C, Al-Saati T, Brousset P, Delsol G (1991) Primary anterior mediastinal B-cell lymphoma. A clinicopathologic and immunohistochemical study of 16 cases. Cancer 67(10):2579\u20132587","journal-title":"Cancer"},{"issue":"9","key":"125_CR29","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.137.9.3013","volume":"137","author":"MP Link","year":"1986","unstructured":"Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA, Levy R (1986) A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 137(9):3013\u20133018","journal-title":"J Immunol"},{"issue":"1","key":"125_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/path.1711520103","volume":"152","author":"K Moore","year":"1987","unstructured":"Moore K, Cooper SA, Jones DB (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 152(1):13\u201321. doi:10.1002\/path.1711520103","journal-title":"J Pathol"},{"issue":"2","key":"125_CR31","first-page":"225","volume":"128","author":"AJ Norton","year":"1987","unstructured":"Norton AJ, Isaacson PG (1987) Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. The American journal of pathology 128(2):225\u2013240","journal-title":"The American journal of pathology"},{"issue":"1","key":"125_CR32","first-page":"181","volume":"128","author":"LJ Picker","year":"1987","unstructured":"Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA (1987) Immunophenotypic criteria for the diagnosis of non-Hodgkin\u2019s lymphoma. The American journal of pathology 128(1):181\u2013201","journal-title":"The American journal of pathology"},{"issue":"3","key":"125_CR33","first-page":"905","volume":"140","author":"R Schwartz-Albiez","year":"1988","unstructured":"Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein Journal of immunology 140(3):905\u2013914","journal-title":"Structure and subcellular expression of an extensively glycosylated glycoprotein Journal of immunology"},{"issue":"1","key":"125_CR34","first-page":"140","volume":"129","author":"HJ Schuurman","year":"1987","unstructured":"Schuurman HJ, van Baarlen J, Huppes W, Lam BW, Verdonck LF, van Unnik JA (1987) Immunophenotyping of non-Hodgkin\u2019s lymphoma. Lack of correlation between immunophenotype and cell morphology The American journal of pathology 129(1):140\u2013151","journal-title":"Lack of correlation between immunophenotype and cell morphology The American journal of pathology"},{"issue":"5","key":"125_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21(5):694\u2013708. doi:10.1016\/j.ccr.2012.03.040","journal-title":"Cancer Cell"},{"issue":"2","key":"125_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123. doi:10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"issue":"Suppl 1","key":"125_CR37","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminhematol.2011.03.003","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni LM, Hartley JA (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 48(Suppl 1):S12\u201323. doi:10.1053\/j.seminhematol.2011.03.003","journal-title":"Semin Hematol"},{"issue":"9","key":"125_CR38","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(9):1492\u20131501. doi:10.1200\/JCO.2008.18.7252","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"9873","key":"125_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. doi:10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0125-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0125-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:55:21Z","timestamp":1678510521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0125-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0125-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,15]]},"assertion":[{"value":"16 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}